PSNL News and Press, Personalis Inc. From 08/08/23

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center H...

2023-08-07 17:35:16 ET Personalis ( NASDAQ: PSNL ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.54 (+10.0% Y/Y) and the consensus Revenue Estimate is $16.49M (-9.4% Y/Y). Over the last 1 year...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p....

2023-06-26 17:28:00 ET Personalis ( NASDAQ: PSNL ) said Monday that it has filed a second patent infringement suit against Foresight Diagnostics Inc. in the U.S. District Court for the District of Colorado. Personalis is seeking injunctive relief and monetary damages. ...

Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Pers...

Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having p...

New findings emphasize the potential of company’s ultra-sensitive MRD platform for longitudinal disease monitoring and the study of dynamic tumor evolution Personalis, Inc. (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Soci...

Multicenter VOLTAGE-2 Phase II Trial Will Conduct Exploratory Biomarker Analysis Using Highly-Sensitive Genomic Platforms from Personalis Personalis, Inc. (Nasdaq: PSNL), National Cancer Center, and Ono Pharmaceutical Co., Ltd. today announced they have entered into a collaborative agre...

2023-05-03 22:23:03 ET Personalis, Inc. (PSNL) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Caroline Corner – Investor Relations Chris Hall – Chief Executive Officer and President Aaron Tachibana – Chief Financ...

2023-05-03 16:40:37 ET Personalis press release ( NASDAQ: PSNL ): Q1 GAAP EPS of -$0.61 misses by $0.05 . Revenue of $18.9M (+24.1% Y/Y) beats by $1.55M . Cash, cash equivalents, and short-term investments of $148.9 million as of March 31, 2023 Personalis...